<?xml version="1.0" encoding="utf-8"?>
<recommendedContent xmlns="http://api.mspoke.com">
    <recommendedItem id="20100101_19_407"
                     title="ICU Catheter Infections Can Be Virtually Eliminated (CME/CE)"
                     score="0.014"
                     href="http://www.medpagetoday.com/CriticalCare/InfectionControl/tb/18308?impressionId=1265806759337"
                     
      Catheter-related infections aren&apos;t inevitable in the ICU, according to a quality initiative that maintained rates at nearly zero for three years in Michigan hospitals.&lt;br&gt;
&lt;br&gt;The maintenance phase, after initial implementation of low-tech measures such as handwashing and removal of unneeded catheters, saw no rebound in catheter-related infections, Peter J. Pronovost, MD, PhD, of Johns Hopkins, and colleagues reported online in &lt;em&gt;BMJ&lt;/em&gt;.&lt;br&gt;
&lt;br&gt;The first 18 months of their &lt;a href=&quot;http://www.medpagetoday.com/InfectiousDisease/GeneralInfectiousDisease/4771&quot; mce_href=&quot;http://www.medpagetoday.com/InfectiousDisease/GeneralInfectiousDisease/4771&quot; target=&quot;_blank&quot;&gt;Keystone ICU initiative&lt;/a&gt; dropped catheter-related interventions from a mean of 7.7 and median of 2.2 per 1,000 catheter days down to 1.3 and 0, respectively.&lt;br&gt;
&lt;br&gt;At the 36 month mark, infection rates remained almost nil, at a mean of 1.1 and median of 0 per 1,000 catheter days.&lt;p&gt;&lt;/p&gt;
&lt;p&gt;&quot;For the most part, hospitals view these infections as inevitable, as the cost of doing business, that patients are too sick, that these can&apos;t be prevented,&quot; Pronovost told &lt;em&gt;MedPage Today&lt;/em&gt;. &quot;That&apos;s just not true.&quot;&lt;/p&gt;
&lt;p&gt;Catheter-related infections are the number one cause of preventable death in hospitals and ICUs, ahead of even ventilator-related pneumonia, he noted.&lt;/p&gt;
&lt;p&gt;The changes seen at the 90 Michigan ICUs that stayed with the catheter-related infection initiative were impressive, representing one of the largest and longest improvements the field has seen.&lt;/p&gt;
&lt;p&gt;Often, quality initiatives fail on durability after the study funding and resources disappear, and hospitals are left on their own, Pronovost noted.&lt;/p&gt;
&lt;p&gt;&quot;If you push you might get some effect, but then you stop pushing  --  in other words the external control goes away  --  and the performance goes right back down,&quot; he said in an interview. &quot;It can&apos;t just be the stick that drives it.&quot;&lt;/p&gt;
&lt;p&gt;The intervention started with 103 ICUs that implemented strategies to reduce rates of catheter-related bloodstream infections rates over 18 months, with measurement and feedback of infection rates.&lt;/p&gt;
&lt;p&gt;The strategies aimed at improving execution of five evidence-based recommendations, as follows: &lt;ul&gt; &lt;li&gt;Hand washing before insertion of the catheter&lt;/li&gt; &lt;li&gt;Using gowns and full barrier precautions at catheter insertion&lt;/li&gt; &lt;li&gt;Cleaning the skin with chlorhexidine before catheter insertion&lt;/li&gt; &lt;li&gt;Avoiding the femoral site when possible&lt;/li&gt; &lt;li&gt;Removing unnecessary catheters&lt;/li&gt; &lt;/ul&gt;&lt;/p&gt;
&lt;p&gt;Then, over the subsequent 18-month maintenance period, ICU teams were instructed to integrate this intervention into staff orientation, to collect monthly data from hospital infection control staff, and to report infection rates to physicians and others.&lt;/p&gt;
&lt;p&gt;Along with the sustained reduction in overall catheter-related infections, the researchers found a prolonged reduction in bloodstream infections that was significant during all study periods, compared to baseline.&lt;/p&gt;
&lt;p&gt;Rates decreased from a mean of 7.7 and median 2.7 of per 1,000 catheter days at baseline to 1.3 and 0, respectively, at 16 to 18 months after implementation. They remained at 1.1 and 0 at months 34 to 36 (-1% versus 18 months, 95% CI -9% to +7%).&lt;/p&gt;
&lt;p&gt;ICU teams interviewed attributed the continuously low rates to five factors: &lt;ul&gt; &lt;li&gt;Continued feedback on infection data&lt;/li&gt; &lt;li&gt;Improvements in safety culture as part of the project&lt;/li&gt; &lt;li&gt;An &quot;unremitting belief in the preventability of bloodstream infections&quot;&lt;/li&gt; &lt;li&gt;Involvement of senior leaders&lt;/li&gt; &lt;li&gt;A noncompetitive, shared goal to reduce infection rates throughout the state&lt;/li&gt; &lt;/ul&gt;&lt;/p&gt;
&lt;p&gt;Of these, Pronovost called culture change in the ICUs the key factor to sustainability, although the researchers cautioned that which aspects contributed were not formally evaluated.&lt;/p&gt;
&lt;p&gt;They said they could not determine the impact incentive payments from Blue Cross Blue Shield of Michigan to hospitals that continued their participation  --  payments that were based on performance thresholds in subsequent years.&lt;/p&gt;
&lt;p&gt;Pronovost&apos;s team is now working to implement the quality initiative state-by-state nationwide, supported by the Agency for Healthcare Research and Technology.&lt;/p&gt;
&lt;p&gt;&quot;It seems absurd that this wouldn&apos;t be in every hospital in the country,&quot; he said in an interview. &quot;It&apos;s worked on a large scale, it&apos;s exceedingly cheap, there&apos;s no fancy technology.&quot;&lt;/p&gt;
&lt;p&gt;Success isn&apos;t only for community hospitals, Pronovost emphasized.&lt;/p&gt;
&lt;p&gt;Large, often academic, medical centers frequently express the conviction that their sicker, more complex ICU population wouldn&apos;t produce the same results, that their infections truly are inevitable, he said.&lt;/p&gt;
&lt;p&gt;&quot;To them I say, Not so,&quot; he told &lt;em&gt;MedPage Today&lt;/em&gt;. &quot;We have shown at Johns Hopkins, at the University of Michigan, at Pittsburgh, using a similar but different approach, at Tufts  --  many large academic medical centers have had dramatic reductions of these infections.&quot;&lt;/p&gt;
&lt;div style=&quot;float:left;border-style:solid;border-width:1px;border-color:#8dabbc;font-family:arial;font-size:12px;background-color:#DBE9F2;padding:5px;&quot;&gt;&lt;p&gt;The project was supported, for the period from October 2003 to September 2005, by the Agency for Healthcare Research and Quality and the Michigan Health &amp;amp; Hospital Association.&lt;/p&gt;&lt;p&gt;Pronovost and a co-author reported receiving received lecture fees from various healthcare organizations and grant support from the Agency for Healthcare Research and Quality, the Robert Wood Johnson Foundation, the National Patient Safety Agency, and the World Health Organization to study and improve quality of care, including catheter-related bloodstream infections.&lt;/p&gt;&lt;p&gt;Co-authors reported conflicts of interest with government agencies, Cubist, Astellas, Merck, Forrest, Cadence, the Robert Wood Johnson Foundation, Lilly, Edward Life Sciences, and Sage.&lt;/p&gt;&lt;/div&gt;&lt;div style=&quot;clear:both;&quot;&gt;&lt;/div&gt;
    </recommendedItem>
    <recommendedItem id="20100101_19_301"
                     title="Tight Glucose Control Fails in Septic Shock (CME/CE)"
                     score="0.004"
                     href="http://www.medpagetoday.com/CriticalCare/Sepsis/tb/18160?impressionId=1265806759337"
                     
      Septic shock patients treated with a corticosteroid get no survival advantage from tight glucose control or addition of a second corticosteroid to provide more mineralocorticoid activity, according to results of a randomized trial.&lt;br&gt;
&lt;br&gt;Aiming for normoglycemia at 80 to 110 mg/dL rather than the standard 150 mg/dL had no impact on inhospital mortality rates (45.9% versus 42.9%, &lt;em&gt;P&lt;/em&gt;=0.50), Djillali Annane, MD, of H&amp;#244;pital Raymond Poincar&amp;#233; in Garches, France, and colleagues found.&lt;br&gt;
&lt;br&gt;Inhospital mortality was likewise similar whether patients got hydrocortisone (Solu-Cortef) alone or with the addition of fludrocortisone ([Florinef] 42.9% versus 45.8%, &lt;em&gt;P&lt;/em&gt;=0.50), they reported in the Jan. 27 issue of the &lt;em&gt;Journal of the American Medical Association&lt;/em&gt;.&lt;/p&gt;
&lt;p&gt;This aggressive treatment strategy should not be routine, the researchers recommended.&lt;/p&gt;
&lt;p&gt;These findings largely match the general lack of benefit seen with tight glycemic control in recent studies with ICU patients overall.&lt;/p&gt;
&lt;p&gt;The prematurely terminated &lt;a href=&quot;http://www.medpagetoday.com/MeetingCoverage/SCCM/5096&quot; mce_href=&quot;http://www.medpagetoday.com/MeetingCoverage/SCCM/5096&quot; target=&quot;_blank&quot;&gt;European Glucontrol Trial&lt;/a&gt; found no mortality benefit but a seven-fold higher risk of hypoglycemia with an 80 to 110 mg/dL target in the ICU.&lt;/p&gt;
&lt;p&gt;In the &lt;a href=&quot;http://www.medpagetoday.com/CriticalCare/Intensivists/13397&quot; mce_href=&quot;http://www.medpagetoday.com/CriticalCare/Intensivists/13397&quot; target=&quot;_blank&quot;&gt;NICE-SUGAR&lt;/a&gt; study, 90-day mortality was actually higher in the tight glucose control group (27.9% versus 24.9%, &lt;em&gt;P&lt;/em&gt;=0.02), although there was a trend for benefit in patients who got corticosteroids (&lt;em&gt;P&lt;/em&gt;=0.06).&lt;/p&gt;
&lt;p&gt;Glucose targets are being re-evaluated across medicine as the &quot;lower is better&quot; paradigm has had a safety asterisk added everywhere from diabetes care to the ICU, noted Richard Bergenstal, MD, American Diabetes Association president for medicine and science.&lt;/p&gt;
&lt;p&gt;&quot;All of a sudden it&apos;s becoming more than a single number,&quot; he told &lt;em&gt;MedPage Today&lt;/em&gt;. &quot;Now be it inpatient or outpatient, we&apos;re realizing that ... you have to do it while you&apos;re minimizing hypoglycemia.&quot;&lt;/p&gt;
&lt;p&gt;A more nuanced and &lt;a href=&quot;http://www.medpagetoday.com/Cardiology/Diabetes/13818&quot; mce_href=&quot;http://www.medpagetoday.com/Cardiology/Diabetes/13818&quot; target=&quot;_blank&quot;&gt;individualized&lt;/a&gt; strategy is prudent, Bergenstal agreed.&lt;/p&gt;
&lt;p&gt;The current clinical uncertainty underscores the need for large-scale international cooperation to get adequately powered trials, according to an accompanying editorial.&lt;/p&gt;
&lt;p&gt;In it, Greet Van den Berghe, MD, PhD, of the Catholic University of Leuven, Belgium, cautioned that Annane&apos;s Corticosteroids and Intensive Insulin Therapy for Septic Shock (COIITSS) study was grossly underpowered.&lt;/p&gt;
&lt;p&gt;The initial studies that led to rapid adoption of intensive insulin therapy in ICUs around the world had suggested an absolute reduction in mortality of only 3%, whereas the COIITSS study projected a 12.5% absolute benefit.&lt;/p&gt;
&lt;p&gt;More importantly, the study achieved mean glucose levels of only between 120 and 130 mg/dL in the intervention group for whom the aim was 80 to 110 mg/dL, which resulted in considerable overlap with the standard care group for whom mean levels were about 145 mg/dL.&lt;/p&gt;
&lt;p&gt;This could account for the lack of difference in outcome, Van den Berghe said.&lt;/p&gt;
&lt;p&gt;But the intensive insulin group did have &quot;markedly&quot; lower blood glucose levels for the duration of their ICU stay and spent more time in the 80 to 110 mg/dL range compared with the standard care group (both &lt;em&gt;P&lt;/em&gt;&amp;lt;0.00001), the researchers noted.&lt;/p&gt;
&lt;p&gt;Because corticosteroids further aggravate the &quot;diabetes of injury&quot; seen with septic shock, Annane&apos;s group undertook a multicenter trial of 509 adults treated for septic shock with multiple organ dysfunction over a three year period at 11 ICUs in France.&lt;/p&gt;
&lt;p&gt;Patients were randomly assigned to tight glucose control using continuous intravenous insulin infusion to target a glucose level of 80 to 110 mg/dL or conventional insulin therapy targeted to guidelines-recommended 150 mg/dL or under. They were additionally randomized to receive hydrocortisone alone (50-mg bolus every six hours) or in combination with fludrocortisone (50-&amp;#956;g tablets once daily) for seven days.&lt;/p&gt;
&lt;p&gt;Aside from the lack of inhospital mortality advantage, tight glucose control also failed to produce a benefit for the following secondary endpoints: &lt;ul&gt; &lt;li&gt;Overall survival (hazard ratio 1.04, &lt;em&gt;P&lt;/em&gt;=0.78) &lt;/li&gt; &lt;li&gt; ICU length of stay for survivors (median 10 versus nine days, &lt;em&gt;P&lt;/em&gt;=0.68)&lt;/li&gt; &lt;li&gt;Duration of hospital stay overall (24 versus 22 days, &lt;em&gt;P&lt;/em&gt;=0.87)&lt;/li&gt; &lt;li&gt;Median vasopressor-free days (four for both, P=0.58)&lt;/li&gt; &lt;li&gt;Median mechanical ventilation-free days (10 versus 13, &lt;em&gt;P&lt;/em&gt;=0.51)&lt;/li&gt; &lt;/ul&gt;&lt;/p&gt;
&lt;p&gt;Nor was there evidence for interaction with fludrocortisone in the primary endpoint (relative risk 0.89 versus 0.91 hydrocortisone alone, &lt;em&gt;P&lt;/em&gt;=0.31) or benefit in any other endpoint.&lt;/p&gt;
&lt;p&gt;The one effect of intensive insulin appeared to be an increase in episodes of severe hypoglycemia, defined by glucose falling below 40 mg/dL (mean 0.29 versus 0.14 episodes per patient, &lt;em&gt;P&lt;/em&gt;=0.003).&lt;/p&gt;
&lt;p&gt;However, having hypoglycemia did not increase the risk of death in intervention group patients compared with controls (45.2% versus 50%).&lt;/p&gt;
&lt;p&gt;The researchers cautioned that the study did not rule out a benefit from some degree of glucose control compared with none.&lt;/p&gt;
&lt;p&gt;They also noted that healthcare providers were not blinded to administration of fludrocortisone, for which no placebo was available.&lt;/p&gt;
&lt;div style=&quot;float:left;border-style:solid;border-width:1px;border-color:#8dabbc;font-family:arial;font-size:12px;background-color:#DBE9F2;padding:5px;&quot;&gt;&lt;p&gt;The study was funded by the Assistance Publique&amp;#8211;H&amp;#244;pitaux de Paris. The researchers reported no conflicts of interest.&lt;/p&gt;&lt;p&gt;Van den Berghe, through the Catholic University of Leuven, reported receiving structural research financing from the Methusalem program, funded by the Flemish government.&lt;/p&gt;&lt;p&gt;Bergenstal reported receiving research funding and serving on advisory boards for various pharmaceutical companies related to novel diabetes drugs but without any personal financial compensation.&lt;/p&gt;&lt;/div&gt;&lt;div style=&quot;clear:both;&quot;&gt;&lt;/div&gt;
    </recommendedItem>
    <recommendedItem id="20100101_19_255"
                     title="Biomarker Guideline Reduced Antibiotic Use (CME/CE)"
                     score="0.001"
                     href="http://www.medpagetoday.com/HospitalBasedMedicine/InfectionControl/tb/18114?impressionId=1265806759337"
                     
      &lt;p&gt;A biomarker-guided strategy for antibiotics in intensive care units reduced drug use without increasing mortality, French researchers said.&lt;/p&gt;
&lt;p&gt;In a randomized, open-label study, the biomarker procalcitonin allowed physicians to reduce the quantity of antibiotics they prescribed, according to Michel Wolff, MD, of H&amp;#244;pital Bichat-Claude-Bernard in Paris, and colleagues.&lt;/p&gt;
&lt;p&gt;In principle, the approach could slow the emergence of antibiotic resistance, Wolff and colleagues concluded online in &lt;em&gt;The Lancet&lt;/em&gt;.&lt;/p&gt;
&lt;p&gt;Procalcitonin is thought to be a &quot;fairly specific marker for severe bacterial infection in patients with suspected sepsis,&quot; the researchers noted in the journal.&lt;/p&gt;
&lt;p&gt;As well, serum procalcitonin concentrations have been shown to be a useful guide to reducing antibiotic use in patients with lower-respiratory-tract infections, they said.&lt;/p&gt;
&lt;p&gt;But the value of the biomarker in reducing inappropriate antibiotic use has not been shown in all intensive care patients, they said. To fill the gap, they conducted a prospective study of 630 patients in eight French ICUs.&lt;/p&gt;
&lt;p&gt;Patients were randomly assigned to be treated according to usual antibiotic protocols or to have their therapy guided by procalcitonin levels.&lt;/p&gt;
&lt;p&gt;For patients in the procalcitonin group, doctors were encouraged to start antibiotics at inclusion if the levels were 0.5 micrograms per liter or greater. Otherwise, they were discouraged from doing so.&lt;/p&gt;
&lt;p&gt;They were also encouraged to stop antibiotics, once started, if the procalcitonin concentration fell by 80% or more from its peak, or if the concentration was below 0.5 micrograms per liter.&lt;/p&gt;
&lt;p&gt;The primary endpoints were death from any cause at 28 and 60 days and differences in antibiotic use.&lt;/p&gt;
&lt;p&gt;The researchers reported: &lt;ul&gt; &lt;li&gt;At 30 days, mortality in the procalcitonin group was 21.2%, compared with 20.4% in the control group, for an absolute difference of 0.8%. That was well below the pre-set 10% difference for non-inferiority.&lt;/li&gt; &lt;li&gt;At 60 days, the comparable figures were 30% and 26.1%, for an absolute difference of 3.8%, which also established non-inferiority.&lt;/li&gt; &lt;li&gt;Patients in the procalcitonin group had 14.3 days without antibiotics, on average, compared with 11.6 days in the control group. The absolute difference of 2.7 days was significant at &lt;em&gt;P&lt;/em&gt;&amp;lt;0.0001.&lt;/li&gt; &lt;/ul&gt;&lt;/p&gt;
&lt;p&gt;The researchers cited a number of limitations, including the open design, which might have permitted bias, and a low number of surgical patients, which may limit how widely the findings can be applied.&lt;/p&gt;
&lt;p&gt;As well, they noted, 53% of patients in the procalcitonin group did not get therapy guided by the study protocol. Despite that, Wolff and colleagues said, the results remained statistically significant if those patients were excluded.&lt;/p&gt;
&lt;p&gt;Various studies have shown that it&apos;s possible to curtail unnecessary antibiotic use in hospitals, according to Marin Kollef, MD, of Washington University School of Medicine in St Louis.&lt;/p&gt;
&lt;p&gt;But because of the limitations of the French study, it remains unclear whether using procalcitonin is the best approach, he wrote in an accompanying editorial.&lt;/p&gt;
&lt;p&gt;&quot;Whether the ideal strategy involves the use of a serum marker such as procalcitonin or a locally applied practice protocol remains to be established,&quot; Kollef concluded.&lt;/p&gt;
&lt;div style=&quot;float:left;border-style:solid;border-width:1px;border-color:#8dabbc;font-family:arial;font-size:12px;background-color:#DBE9F2;padding:5px;&quot;&gt;&lt;p&gt;The study was supported by the Assistance Publique-H&amp;#244;pitaux de Paris, France, and Brahms, Germany. Wolff reported financial links with Merck Sharp &amp;amp; Dohme-Chibret, Janssen-Cilag, Gilead, and AstraZeneca.&lt;/p&gt;&lt;p&gt;Kollef reported no conflicts.&lt;/p&gt;&lt;/div&gt;&lt;div style=&quot;clear:both;&quot;&gt;&lt;/div&gt;
    </recommendedItem>
    <recommendedItem id="20090101_19_841"
                     title="World TB Stable, U.S. Rates Lowest Since 1953"
                     score="-0.005"
                     href="http://www.medpagetoday.com/InfectiousDisease/GeneralInfectiousDisease/tb/13342?impressionId=1265806759337"
                     
      GENEVA, March 19 -- The number of new tuberculosis cases grew slowly in 2006, the World Health Organization reported, with most of the increase attributable to population growth.
              &lt;p&gt; 
              &lt;p&gt;Although the global trends were generally positive, WHO officials said they&apos;re concerned about the growth in multidrug-resistant (MDR) strains of TB, as well as the organization&apos;s ability to detect new cases.
              &lt;p&gt; 
              &lt;p&gt;&quot;Overall, there are several signs that global progress in TB control is slowing and that there are parts of the world where much more needs to be done to achieve global targets that have been set,&quot; the report states.
              &lt;p&gt; 
              &lt;p&gt;Meanwhile, the U.S. Centers for Disease Control and Prevention reported continued progress here: in 2008 the American TB rate declined to 4.2 cases per 100,000 population, the lowest since national reporting began in 1953.
              &lt;p&gt; 
              &lt;p&gt;All told, there were 12,898 new cases, down from 13,228 in 2007, the agency said in the March 20 &lt;em&gt;Morbidity and Mortality Weekly Report&lt;/em&gt;.
              &lt;p&gt; 
              &lt;p&gt;Nonetheless, the agency said, the picture is not entirely rosy, since foreign-born people and members of racial or ethnic minorities continued to bear a disproportionate burden of TB disease. Specifically:
              &lt;p&gt; 
              &lt;ul&gt;
                &lt;li&gt;The 2008 TB rate among foreign-born persons was 10 times higher than in native-born people -- 20.2 per 100,000 population compared with 2.0. That said, the rate fell by 2.6% compared with 2007.
              &lt;li&gt;TB rates among Hispanics and blacks were nearly eight times higher than among non-Hispanic whites, at 8.1 and 8.7 cases, respectively, per 100,000 population compared with 1.1.
              &lt;li&gt;The rate among Asians was 25.1 cases per 100,000 population -- nearly 23 times higher than among non-Hispanic whites.
              &lt;/ul&gt;
              &lt;p&gt; 
              &lt;p&gt;The worldwide 2006 findings, which run two years behind national figures,  came from an annual collection of data by WHO from 202 countries and territories in 2007.
              &lt;p&gt; 
              &lt;p&gt;The report found an estimated 9.2 million new cases of TB, up by about 100,000 (about 1%) from the previous year. About 8% of the new cases involved HIV-positive patients. 
              &lt;p&gt; 
              &lt;p&gt;Altogether, about 14.4 million people were infected with TB worldwide.
              &lt;p&gt; 
              &lt;p&gt;WHO said most of the case growth in 2006 was the result of population increases, particularly in India and China.
              &lt;p&gt; 
              &lt;p&gt;India, China, Indonesia, South Africa and Nigeria rank highest in terms of absolute numbers of cases. The African Region has the highest incidence rate per capita (363 per 100 000 population).
              &lt;p&gt; 
              &lt;p&gt;There were 1.7 million TB-related deaths in 2006. Of those, almost 14% were co-infected with HIV. 
              &lt;p&gt; 
              &lt;p&gt;Overall, the report said, the worldwide fight against TB has been successful since the 1990s in terms of incidence, prevalence and mortality.
              &lt;p&gt; 
              &lt;p&gt;The number of new cases has fallen globally since 2003 in all six WHO regions except Europe, where rates are stable. However, WHO&apos;s annual report expressed concern about several battlefronts.
              &lt;p&gt; 
              &lt;p&gt;For example, new case detection grew only 3%, down from an increase of 6% each year prior, according to a new World Health Organization progress report. 
              &lt;p&gt; 
              &lt;p&gt;Although 700,000 TB patients were tested for HIV in 2006, that&apos;s slightly less than half of WHO&apos;s 1.6 million target. Still, officials noted that it was a considerable increase over the 22,000 TB patients tested for HIV in 2002 and 470,000 in 2005.
              &lt;p&gt; 
              &lt;p&gt;The numbers tested in 2006 are equivalent to 12% of TB case noti?cations globally, and 22% of noti?ed cases in the African Region.
              &lt;p&gt; 
              &lt;p&gt;African nations with the highest HIV testing rates in TB patients were Rwanda (76%), Malawi (64%), and Kenya (60%). 
              &lt;p&gt; 
              &lt;p&gt;The progress report also found that budgets for national TB control programs have remained stagnant from 2007, at about $1.8 billion in 2008.
              &lt;p&gt; 
              &lt;p&gt;&quot;Renewed effort to accelerate progress in global TB control . . . supported by intensified resource mobilization from domestic and donor sources is needed,&quot; the report states.
              &lt;p&gt; 
              &lt;p&gt;The report cited two other major barriers to progress -- cases of multidrug-resistant TB (MDR-TB) and the prevalence of patients with HIV and TB. 
              &lt;p&gt; 
              &lt;p&gt;MDR-TB reached the highest levels ever recorded, with 500,000 new cases reported in 2006, but international response has been slow, the report said. Countries project that they will provide treatment to only 10% of patients with MDR-TB in 2008.
              &lt;p&gt; 
              &lt;p&gt;Additional reporting by Michael Smith, &lt;em&gt;MedPage Today&lt;/em&gt; North American Correspondent.
          
    </recommendedItem>
    <recommendedItem id="20090101_19_1010"
                     title="Clinical Rule Predicts &lt;em&gt;C. Diff&lt;/em&gt; Recurrrence"
                     score="-0.005"
                     href="http://www.medpagetoday.com/InfectiousDisease/GeneralInfectiousDisease/tb/13545?impressionId=1265806759337"
                     
      TORONTO, April 1 -- A simple clinical rule can predict which patients with &lt;em&gt;Clostridium difficile&lt;/em&gt; infection are at risk for recurrence, researchers in Boston said.
              &lt;p&gt; 
              &lt;p&gt;The method correctly identified 77.3% of patients who had recurrent infection in a derivation cohort studied in 1998, according to Ciar�n P. Kelly, M.D., of Harvard Medical School, and colleagues.
              &lt;p&gt; 
              &lt;p&gt;And in an independent validation cohort, studied between December 2004 and May 2006, the method picked up 71.9%, the researchers reported in the April issue of &lt;em&gt;Gastroenterology&lt;/em&gt;.
              &lt;p&gt; 
              &lt;p&gt;&lt;em&gt;C. difficile&lt;/em&gt; has become the leading cause of hospital-acquired infectious diarrhea. It affects millions of patients a year. Multiple recurrences are common, despite successful treatment of the initial episode
              &lt;p&gt; 
              &lt;p&gt; &quot;This rule is valuable in clinical practice as it defines a high-risk population in whom awareness of the risk can facilitate more prompt recognition, diagnosis, and treatment of recurrent &lt;em&gt;C. difficile&lt;/em&gt;,&quot; Dr. Kelly said in a statement.
              &lt;p&gt; 
              &lt;p&gt;The rule combines three variables: age, disease severity, and antibiotic use. A second rule, involving immune responses, appeared to work well in the derivation cohort, but was less successful in the validation group, the researchers said.
              &lt;p&gt; 
              &lt;p&gt;The derivation cohort contained 63 patients, of whom 19 died during follow-up and could not be assessed for recurrence. Among the remaining 44 patients, 22 (50%) had recurrence.
              &lt;p&gt; 
              &lt;p&gt;In the validation cohort, 89 patients were enrolled, including 15 who died during follow-up, and three who were lost to follow-up. Seven others were excluded because they could not be classified as either recurrence or no recurrence, leaving 64 in the analysis. Of those, 13 had a recurrence.
              &lt;p&gt; 
              &lt;p&gt;Data from the validation cohort were subjected to regression analysis, and factors that significantly predicted recurrence were age greater than 65, severe or fulminant disease on the Horn index, and additional antibiotic use after the end of &lt;em&gt;C. difficile&lt;/em&gt; therapy.
              &lt;p&gt; 
              &lt;p&gt;The model using those factors distinguished between patients at risk and not at risk, with an area under the receiver operating characteristic curve of 0.83.
              &lt;p&gt; 
              &lt;p&gt;Specifically, of the 44 patients, 22 were in the high-risk group using the model and of those, 17 (or 77.3%) had recurrence, compared with five (or 22.7%) in the low-risk group.
              &lt;p&gt; 
              &lt;p&gt;In the validation group, 19 patients were classified as high-risk and recurrence occurred in seven (or 36.8%);, 45 were seen as low-risk, with recurrence in six (or 13.3%).
              &lt;p&gt; 
              &lt;p&gt;The area under the receiver operating characteristic curve was 0.80, the researchers said.
              &lt;p&gt; 
              &lt;p&gt;They noted that one limitation of the analysis was the relatively small number of patients with recurrence in the validation cohort. Also, they said, the rule includes a factor -- the Horn index -- that requires subjective interpretation.
              &lt;p&gt; 
              &lt;p&gt;Because there are no uniformly successful therapies for recurrent &lt;em&gt;C. difficile&lt;/em&gt; infection, new treatments are needed, said Christina M. Surawicz, M.D., of the University of Washington in Seattle, in an accompanying editorial.
              &lt;p&gt; 
              &lt;p&gt;And because only about 10% to 20% of patients relapse, some way of identifying them for clinical trials -- in order to test new treatments -- is essential, she said.
              &lt;p&gt; 
              &lt;p&gt;She called the Boston study &quot;an important step&quot; in that direction.
              &lt;p&gt; 
              &lt;p&gt;&quot;This trio of factors is easy to use clinically and will be useful to aid future research as more effective therapies are sorely needed,&quot; she argued.
              &lt;p&gt; 
              &lt;p&gt; 
              &lt;p&gt;&lt;table cellspacing=&quot;0&quot; hspace=&quot;1&quot; style=&quot;border-style:solid; border-width:1px; border-color:#8dabbc; font-family:arial; font-size:12px; background-color:#DBE9F2; padding:5px 5px 5px 5px;&quot;&gt;
&lt;tr&gt;&lt;td&gt;The study was supported by the NIH, Harvard Medical School, and the Irish Health Research Board.
              &lt;p&gt; 
              &lt;p&gt;Dr. Kelly reported financial links with Acambis, Actelion, BioHelix, Genzyme, Replidyne, Salix, Massachusetts Biologics Laboratories, Medarex Inc., and ViroPharma, some of which are producing or developing treatments for &lt;em&gt;C. difficile&lt;/em&gt; infection.
              &lt;p&gt; 
              &lt;p&gt;Dr. Surawicz reported financial links with ViroPharma and Biocodex&lt;/td&gt;&lt;/tr&gt;&lt;/table&gt;
       
    </recommendedItem>
</recommendedContent>